Prostate cancer detection in patients with total serum prostate-specific antigen levels of 4–10 ng/mL: Diagnostic efficacy of MicroRNA-141
| Autor: | Abdulkadir Cat, Tülay Köken, Mustafa Karalar |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
medicine.medical_specialty
Receiver operating characteristic business.industry 030232 urology & nephrology Area under the curve Urology General Medicine Hyperplasia urologic and male genital diseases medicine.disease Fold change Reverse transcription polymerase chain reaction 03 medical and health sciences Prostate cancer 0302 clinical medicine Antigen 030220 oncology & carcinogenesis microRNA medicine business |
| Zdroj: | Clinical Cancer Investigation Journal. 6:10 |
| ISSN: | 2278-0513 |
| DOI: | 10.4103/ccij.ccij_16_17 |
| Popis: | Objective: The purpose of this small pilot study was to evaluate the utility of microRNA-141 (miR-141) as a biomarker for detecting prostate cancer (PCa) in patients with total serum prostate-specific antigen (PSA) levels of 4–10 ng/mL, which is referred to as the “gray zone.” Materials and Methods: Eleven PCa patients, 23 benign prostatic hyperplasia (BPH) patients with PSA levels of 4–10 ng/mL, and 16 healthy controls were enrolled in this study. Total RNA was extracted from serum samples, and the level of miR-141 was analyzed by quantitative reverse transcription polymerase chain reaction. Results: The circulating miR-141 level was significantly higher in PCa patients than in BPH patients and healthy controls (fold change [mean ± standard deviation], 0.528 ± 0.083 for PCa, 0.297 ± 0.038 for BPH, and 0.262 ± 0.025 for controls; P< 0.05). Receiver operating characteristic curve revealed that the serum miR-141 yielded an area under the curve of 0.751, with 72% sensitivity and 92% specificity in discriminating patients with PCa from BPH patients with total serum PSA levels in the gray zone. Conclusion: The present results indicate that miR-141 expression is significantly increased in the peripheral blood of patients with PCa compared with BPH patients and healthy individuals. We think that miR-141 may guide clinicians during the decision phase of patients with PCa and BPH in the PSA gray zone. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|